Clinical Trial: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara(R) (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07340658) titled 'A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara(R) (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer' on Jan. 09.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara(R) (oral tablet), both given together with palbociclib, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Advance...